



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



Carbendazim

Cat. No.:	HY-13582
CAS No.:	10605-21-7
Molecular Formula:	C ₉ H ₉ N ₃ O ₂
Molecular Weight:	191.19
Target:	Fungal; Parasite
Pathway:	Anti-infection
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 6.8 mg/mL (35.57 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		5.2304 mL	26.1520 mL	52.3040 mL
		5 mM		1.0461 mL	5.2304 mL	10.4608 mL
		10 mM		0.5230 mL	2.6152 mL	5.2304 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 0.5 mg/mL (2.62 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 0.5 mg/mL (2.62 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Carbendazim is a potent and orally active broad-spectrum benzimidazole fungicide and can be acts as a pesticide for fungal diseases research, such as Seproria, Fusarium and Sclerotina ^{[1][3]} . Carbendazim is a benzimidazole (HY-Y1825) derivative with antitumor activity and used for cancer research, especially advanced solid tumors and lymphoma ^[3] .
In Vitro	Carbendazim (4-60 μM; 24 hours) has no effects on viability of HeLa cells in a CCK-8 assay ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Carbendazim (oral gavage; 100 and 500 mg/kg; once daily in diet; 28 days) induces hepatic lipid metabolism disorder, it results in a significant increase of hepatic lipid accumulation and triglyceride (TG) levels in mice ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-week-old male ICR mice ^[2]
Dosage:	100 and 500 mg/kg
Administration:	Oral gavage; 100 and 500 mg/kg; once daily in diet; 28 days
Result:	Increased the relative mRNA levels of some key genes related to lipogenesis and TG synthesis. Up-regulated mRNA levels of IL-1b and IL-6 in the liver in mice. Increased the serum concentrations of 2 proinflammatory cytokines IL-1b and IL-6 at 500 mg/kg. However, in the fat tissues, only IL-1b in the CBZ-500-treated group increased significantly as compared with the control group.

CUSTOMER VALIDATION

- Chemosphere. 2022 Jan 4;133522.
- Chemosphere. 2021, 130769.
- Toxics. 2021, 9(12), 349.
- Research Square Preprint. 2021 Aug.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Carbendazim

[2]. Yuanxiang Jin, et al. Oral Exposure of Mice to Carbendazim Induces Hepatic Lipid Metabolism Disorder and Gut Microbiota Dysbiosis. Toxicol Sci. 2015 Sep;147(1):116-26

[3]. Bilge G. Tuna, et al. Enhanced antitumor activity of carbendazim on HeLa cervical cancer cells by aptamer mediated controlled release. RSC Advances

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA